Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emfilermin

Drug Profile

Emfilermin

Alternative Names: AM 424; Leukaemia inhibitory factor; Leukemia inhibitory factor; LIF; recombinant leukaemia inhibitory factor; Recombinant leukaemia inhibitory factor protein - Ares-Serono; Recombinant LIF protein - Ares-Serono; rhLIF

Latest Information Update: 02 May 2005

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Walter and Eliza Hall Institute of Medical Research
  • Class Cytokines; Neuroprotectants
  • Mechanism of Action Leukaemia inhibitory factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Female infertility; Neuromuscular disorders

Most Recent Events

  • 23 Jun 2004 Data from a media release have been added to the Women's Health therapeutic trials section
  • 04 Jun 2004 Serono has completed the international proof-of-concept phase II trial with emfilermin for female infertility
  • 07 Jul 2003 Data from a media release have been added to the adverse events and Women's health therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top